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CCM = critical care medicine; CPR = cardiopulmonary resuscitation; ICU = intensive care unit; PCR = polymerase chain reaction.
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Introduction
Critical care medicine (CCM) and the intensive care unit
(ICU) are essential components of modern health care
systems around the globe. CCM has the capability of
reversing near-fatal states and of temporarily supporting
failing vital functions, systems and organs, while the
patient recovers from the underlying disease process. The
ICU is not the domain of any specialty; for appropriate
care, four major disciplines (anesthesiology, internal medi-
cine, surgery, and pediatrics) have been working collabo-
ratively because patients admitted to ICUs often have
multiple system organ diseases. Intensive care physicians
have, since the 1970s, been transforming medicine by
integrating knowledge derived over generations with
modern medical research and information technology.
Over the past three decades, the data set employed by
critical care physicians was based largely on physiologi-
cal and pharmacological concepts, typified by the skills
required to perform cardiopulmonary resuscitation (CPR),
and was well taught in all training programs. In the current
century, we argue that the skill set required to adequately
treat critically ill patients will also require knowledge of
molecular biology for diagnosis and treatment. Molecular
biology holds the promise of transforming medicine; its
foundations are essential for the understanding of the
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Abstract
As in other areas of medicine, the specialty of critical care medicine, which has made important
contributions in the pathophysiology of critical illness, is facing challenges that must be recognized and
addressed in the current century. In this review, we argue that the skill set required to adequately treat
critically ill patients will also require knowledge of molecular biology for better diagnosis and treatment.
The foundations of molecular biology and genetics are essential for the understanding of the
mechanisms of disease. Incorporating molecular biology techniques in the research arsenal of the
intensivist will provide the opportunity to dissect out and define the reversible and irreversible
intracellular processes giving rise to the major causes of mortality in intensive care units. Two historical
paradigms, the cardiopulmonary resuscitation and polymerase chain reaction, summarize how critical
care medicine began, and how it could mature in the years to come.
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mechanisms of life. A metaphor for this knowledge set is
the polymerase chain reaction (PCR). The two historical
paradigms of CPR and PCR summarize how CCM
began, and how it could mature in the years to come to
pursue its ultimate goal: to return a critically ill patient to a
happy and productive life. Whether they are hereditary or
not, many diseases and pathophysiological disturbances
have a genetic background. Classic genetics states that
the genotype is responsible for the phenotype. It seems
clear, however, that the pathogenesis of most diseases is
the result of complex interactions among the genotype,
the environment, and the nature of the process that leads
to cell, tissue, organ, or systemic injury. As the molecular
knowledge of normal physiology and disease becomes
clearer, we may be able not only to prevent illness, but
also to design accurate genetic tests and individualized
treatments.
CPR and CCM: a parent and child relationship
CCM is a very young medical specialty. Failure to breathe
was, until the early 1950s, considered synonymous with
the failure to survive. The introduction of the negative-pres-
sure whole-body ventilator or ‘iron lung’ during the
poliomyelitis epidemic in Europe and North America chal-
lenged the concepts of life and death, and began a new
page in the history of medicine [1]. Extension of the iron
lung concept to other patients with acute respiratory prob-
lems, and the emerging development of modern anesthe-
sia and cardiac surgery, soon led to the introduction of a
group of life-support techniques. Endotracheal intubation
became the optimal method of securing the airway.
Although peripheral venous cannulation was often quicker
and easier, the central veins became the optimal routes for
delivering drugs rapidly into central circulation. For the first
time in medical history, physicians were able to reverse
terminal states and to revive or resuscitate patients in
near-death or clinical death situations [2,3]. By the early
1960s, modern CPR became available not only in hospital
emergency departments and operating and recovery
rooms [4], but also in the out-of-hospital setting [5]. By
1970, physicians were able to support almost every organ
function; death became a neurological concept instead of
a cardiological concept, and the term CPR was extended
to cardiopulmonary–cerebral resuscitation [6]. All steps in
relation to CPR became available when the techniques of
‘basic’ and ‘advanced’ life support gave birth to ‘pro-
longed’ life support, with the development of the ICU
concept. With the introduction of prolonged endotracheal
intubation, mechanical ventilation, continuous electrocar-
diogram monitoring, bedside intravascular catheterization,
analysis of respiratory gases in arterial and venous blood,
closed-chest cardiac massage and defibrillation, and the
development of new anesthetic agents, it was possible to
support life and improve the outcome of patients in various
surgical states and medical conditions. The first modern
ICUs were born [7,8].
A critically ill patient can be defined as a patient with a
physiologic disorder who is experiencing an ongoing
threat to the integrity of the cardiorespiratory system and
who has a high likelihood of requiring aggressive life
support. The advances in the treatment of such patients
followed advances in other medical and surgical disci-
plines that were instrumental in the implementation and
consolidation of modern ICUs. Much credit has, however,
to be given to improvements in monitoring skills, tech-
niques, and equipment. Although well-trained anesthesiol-
ogists were the specialists who contributed the most to
the birth of modern ICUs [9], many other medical and sur-
gical disciplines soon began to cooperate for care of the
seriously ill patient. Because intensive care medicine
requires team action by physicians, nurses, and other
health professionals with various specialty backgrounds
and added expertise in resuscitation, the need for well-
trained, full-time ‘intensivists’ and nurses working in the
ICU was followed by the development of education guide-
lines, fellowship training programs within a multidiscipli-
nary approach, and the development of national and
international societies of Intensive and Critical Care Medi-
cine in the USA and Europe [10–12]. Qualified critical
care physicians must be trained to address the complex
problems of multiple system organ dysfunction as they
possess the requisite knowledge, skill, interest, judgment,
and frequency of exposure to treat most problems of criti-
cally ill patients directly, and as they are physically present
to address them [13].
In the first two decades of the modern history of CCM,
emphasis was placed on the needs of patients with acute
respiratory failure and multiple system organ failure. The
latter is not a specific disease caused by any specific
factor, but it is well established that the number of addi-
tional organs involved in the disease process, not the organ
itself, appears to determine mortality in the critically ill
patient requiring prolonged life support [14]. It is currently
agreed that multiple system organ failure or dysfunction is
the result of an inappropriate response of the host to a
variety of challenges, such as severe infection, severe
trauma or severe inflammation. Hemodynamic monitoring
with bedside catheterization techniques was essential for
the understanding, better management and treatment of
patients with acute pulmonary edema and shock. The diver-
sity of patients, the implementation of ICUs around the
world, the inadequate information on ICU outcome, and the
rapid incorporation of new medical discoveries, in conjunc-
tion with the use of sophisticated technology, soon
prompted the evaluation of different therapeutic protocols
and clinical research. Technology forced the stratification
of patients by severity and type of illness [15] because
expensive equipment could not be widely used in every
sick patient. The physiological and pharmacological
support of patients in the ICU has, as a result, been very
effective to date. Several studies have demonstrated thatc
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the input of a critical care specialist to an academically affil-
iated hospital both lowers the mortality rate and reduces
the number of days of ICU and hospital care [16–18].
Molecular critical care medicine: from CPR to
PCR
It seems probable that all fields of medicine will change
more in the next decade than they have in the past 2000
years. The main drivers of this change are molecular
biology and information technology. Whether directly
involved or merely an interested observer, one cannot fail
to recognize that the remarkable progress in understand-
ing disease pathogenesis at the cellular and molecular
level has placed us on the threshold of a new, revolution-
ary era of clinical practice. A decade ago, little was known
about how cells communicate or how they transduce
stimuli. The development of an ever-expanding armamen-
tarium of technologies for analysis of gene structure and
function, referred to as recombinant DNA (deoxyribonu-
cleic acid) technology, has created unprecedented oppor-
tunities for significantly improving the treatment and
prevention of human diseases. Recombinant DNA technol-
ogy has made it possible to study the molecular factors
modulating cellular responses to metabolic and environ-
mental stresses. The application of molecular biology to
elucidating the causes and potential cures of disease has
become a major thrust of research at virtually all medical
institutions. Incorporating molecular biology techniques in
the research arsenal of the critical care physician will
provide the opportunity to dissect out and define the
reversible and irreversible intracellular processes giving
rise to acute respiratory distress syndrome, sepsis, septic
shock, and multiple system organ failure (ie the major
causes of mortality in most ICUs) [19,20] (Table 1).
The specialty of CCM, which has made important contri-
butions in the pathophysiology of critical illness, is facing
challenges that must be recognized and addressed as we
enter the new century. Compared with other specialties, a
parallel momentum for exploiting these technologies has
been relatively slow to develop in the field of CCM.
Despite the enormous literature pertaining to the molecu-
lar biology of the cell that has evolved over the past
decade, most intensivists have little understanding of the
profound impact of molecular biology in the practice of
their own specialty. Discoveries in most biological systems
highlight the need to connect physiology with genetics,
molecular and cellular biology. Much attention has been
focused in recent years on the Human Genome Project,
an international effort that has been able to delineate the
entire DNA sequence of Homo sapiens [21,22]. The infor-
mation derived from knowledge of the human genome
sequence, when combined with the increasingly sophisti-
cated tools of molecular biology, will certainly radically
alter medical practice.
Recombinant DNA techniques allow us to examine a gene’s
structural integrity and to assess gene expression at the
mRNA and protein level. A widely used approach for evalu-
ating gene expression involves use of PCR, a technique that
can be applied to the assessment of gene expression using
small quantities of tissue. PCR allows us to amplify and
Available online http://ccforum.com/content/5/3/125
Table 1
Relation of physiological events with clinical presentation and molecular biology in some acute illnesses
Disease/syndrome Physiological event Clinical presentation Molecular process Potential new therapy
Bacterial pneumonia Alveolar exudate Pulmonary dysfunction Change in cell surface  Inhaled anti-inflammatory 
receptor affinity for  cytokines
Inflammatory infiltrates microorganisms
Antibiotic therapy based on 
Cell damage Immune suppression bacterial DNA susceptibility
Shock Tissue ischemia Organ hypoperfusion Upregulation of ROS Endothelial growth factors
Endothelial damage Reduced NOS synthesis ROS scavengers
Ventilator-induced  Alveolar disruption Respiratory failure Decreased synthesis and  Lung protective ventilatory 
lung injury denaturation of surfactant strategies
Alveolar/interstitial edema
Upregulation of inflammatory  Inhaled anti-inflammatory 
Capillary stress cytokines cytokines
SIRS Immune suppression Multiple organ dysfunction Upregulation of acute phase  IL-10 gene expression vector
proteins and cytokines
Sustained low grade  Blocking EBP cellular 
inflammation receptors
EBP, Endotoxin binding proteins; IL-10, interleukin-10; NOS, nitric oxide synthase; ROS, reactive oxygen species; SIRS, systemic inflammatory
response syndrome.identify specific segments of DNA by a simple chemical
reaction within a few hours. PCR involves the exponential
amplification of a selected DNA segment more than
1 million-fold by the induction of repeated cycles of DNA
synthesis from a given DNA template. The strategy is similar
to the process of DNA synthesis utilized by all living organ-
isms. PCR has fostered an explosion of research in the
diagnosis of genetic and infectious diseases. The molecular
changes seen in critically ill tissues and organs are either
exaggerations of normal physiology or inappropriate expres-
sion of repair patterns. The cellular events involved in medi-
ating organ inflammation, tissue damage, and repair are
ultimately controlled at the molecular level and cannot be
fully understood without consideration of the functions of
the relevant genes and their products. Using PCR and other
molecular biology techniques, critical care scientists have
evaluated their potential use in the detection of pulmonary
and systemic infections [23,24], in systemic and local
cytokine expression during the intense host inflammatory
response seen in patients with sepsis and acute lung injury
[25,26], and to examine the genetic susceptibility to poor
outcome during critical illness [27].
Biotrauma: a paradigm for molecular CCM
DNA, mRNA or proteins can be extracted from the lung or
any tissue or cell population using standard biochemical
techniques. In conjunction with PCR technology, we can
assess the relevance of altered gene transcription and
translation to given physiological and pathological states.
Epithelial and endothelial cells respond to lung injury with
acute alterations in mediator generation and surface mole-
cule expression, and appear to act in concert with inflam-
matory cells to influence the lung tissue response to injury
and inflammatory stimuli. These interactions are in turn
known to induce the expression of various genes encod-
ing proteins central to coagulation, fibrinolysis, and repair.
The influence of these molecules on a particular cell or cell
population may be influenced greatly by interactions with
cytokines and other types of regulatory factors (Fig. 1).
Research over the past decade has shown that mechanical
ventilation per se could lead to a number of serious compli-
cations, including the initiation or exacerbation of an under-
lying lung injury, and might contribute to the development
of multiple system organ failure [28]. Recent reports
[29–31] are instrumental in understanding the inflammatory
aspects of the pathogenesis of ventilator-induced lung
injury and the influence of different ventilatory patterns on
the pulmonary and systemic inflammatory responses.
These experimental studies have demonstrated that cyclic
mechanical stress imposed on airway epithelium with con-
ventional mechanical ventilation may lead to the activation
of alveolar macrophages, which then release pro-inflamma-
tory cytokines from the lungs during less than 3 hours of
ventilation. This implies that the activation of intra-alveolar
cells occurs very early on, before any signs of lung injury
become apparent. Molecular studies of gene expression
using PCR technology have revealed that the induction of
marked increases in the expression of certain cytokines fol-
lowing lung injury often correlates with the magnitude of
lung damage. Although there are various differences
between these experimental models and the clinical
setting, these reports support the hypothesis that certain
current techniques and strategies of mechanical ventilation
might contribute to the development of a systemic inflam-
matory response and multiple system organ failure. A more
recent randomized clinical trial has confirmed that pul-
monary and systemic cytokine response can be minimized
by limiting recruitment or de-recruitment of collapsed lung
units, or overdistension of alveolar regions [32]. We have
largely underestimated the complexity of the inflammatory
and immune systems, and of their interactions in severely ill
patients. Propagation of inflammatory signals from the air-
space to the vascular space is pivotal in lung inflammation,
but mechanisms of inter-compartmental signaling are still
not well understood. Tumor necrosis factor-a induces sig-
naling between the alveolar and vascular compartments of
the lung; this novel mechanism may be relevant in the alve-
olar recruitment of leukocytes [33]. Increasing evidence
also suggests that pulmonary dysfunction results from
acute oxygen toxicity because of the injury and death of
lung cells. Altered expression of several apoptotic regula-
tory proteins, such as p53 and Bcl-2, is associated with
hyperoxic cell death and lung injury [34]. The development
of an oxidant/antioxidant imbalance during lung inflamma-
tion may activate sensitive transcription factors, such as
nuclear factor-kB, which regulate the genes for pro-inflam-
matory mediators and protective antioxidant genes.
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Figure 1
A network of networks between cytokines and other regulatory factors.
IL, Interleukin; NF, nuclear factor; NOS, nitric oxide synthase; PMN,
neutrophils; ROS, reactive oxygen species; RT-PCR, reverse
transcription and polymerase chain reaction.From ABC (airway, breathing, circulation) to
MGM (molecular and genetic medicine)
From a therapeutic point of view, modern molecular
methods are being developed that allow the stable trans-
fer of foreign DNA sequences into human and other mam-
malian somatic cells. Promising approaches based on the
delivery of genes, either as plasmid DNA or by viral
vectors, have been extensively evaluated preclinically and
in early-phase clinical trials. Plasmids are like viruses living
parasitically in bacteria. More than 100 clinical gene
therapy studies have actually been currently approved.
There is now an impressive range of potential treatments
including gene therapy, anti-cytokine and anti-adhesion
molecule approaches, and targeting of intracellular signal
transduction pathways [35]. Recombinant retrovirus con-
structs containing a cytokine-cDNA can be used to infect
cells in vitro and to obtain information regarding the patho-
genesis and treatment of several processes that are rele-
vant in clinical diseases [36]. Blocking cytokine activation
or pharmacological effects with specific cytokine-receptor
antagonists represents a logical strategy for the treatment
or attenuation of sepsis-related inflammation. Strategies
that make it possible to selectively downregulate the
effects of specific cytokines would be particularly attrac-
tive from the therapeutic perspective.
All areas of medical research are being affected by the
explosion of knowledge and technology in the fields of cel-
lular and molecular biology. The new intellectual challenge
is to reintegrate this information into an understanding of
whole tissue, organ and organism function. DNA is cer-
tainly part of our destiny [20]. For this reintegration to
occur, physicians taking care of patients with critical prob-
lems must understand the basic science and technology
of molecular biology. As in other specialties, intensive and
critical care societies should advocate the need for
mandatory training in molecular biology techniques during
CCM training programs, not only to provide the transition
for clinical application of molecular biological advances,
but also to keep the basic science research on track. It is
an exciting time for respiratory and critical care medicine.
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